scholarly journals Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?

2016 ◽  
Vol 1 (3) ◽  
pp. 115-121 ◽  
Author(s):  
Yi Dong ◽  
Wenjie Cao ◽  
Xin Cheng ◽  
Kun Fang ◽  
Fei Wu ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Low Dose ◽  
Intravenous Tissue Plasminogen Activator ◽  
Tissue Plasminogen

scholarly journals Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review

2018 ◽  
Vol 3 (1) ◽  
pp. 28-33 ◽  
Author(s):  
Xia Wang ◽  
Shoujiang You ◽  
Shoichiro Sato ◽  
Jie Yang ◽  
Cheryl Carcel ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Low Dose ◽  
Standard Dose ◽  
Meta Analysis ◽  
Cochrane Central Register ◽  
Risk Of Death ◽  
Tissue Plasminogen

The optimal dose of recombinant tissue plasminogen activator (rtPA) for acute ischaemic stroke (AIS) remains controversial, especially in Asian countries. We aimed to update the evidence regarding the use of low-dose versus standard-dose rtPA. We performed a systematic literature search across MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) from inception to 22 August 2016 to identify all related studies. The outcomes were death or disability (defined by modified Rankin Scale 2–6), death, and symptomatic intracerebral haemorrhage (sICH). Where possible, data were pooled for meta-analysis with ORs and corresponding 95% CIs by means of random-effects or fixed-effects meta-analysis. We included 26 observational studies and 1 randomised controlled trial with a total of 23 210 patients. Variable doses of rtPA were used for thrombolysis of AIS in Asia. Meta-analysis shows that low-dose rtPA was not associated with increased risk of death or disability (OR 1.13, 95% CI 0.95 to 1.33), or death (OR 0.86, 95% CI 0.74 to 1.01), or decreased risk of sICH (OR 1.06, 95% CI 0.65 to 1.72). The results remained consistent when sensitivity analyses were performed including only low-dose and standard-dose rtPA or only Asian studies. Our review shows small difference between the outcomes or the risk profile in the studies using low-dose and/or standard-dose rtPA for AIS. Low-dose rtPA was not associated with lower risk of death or disability, death alone, or sICH.

Outcomes of intravenous tissue plasminogen activator for acute ischaemic stroke in HIV-infected adults

2014 ◽  
Vol 21 (11) ◽  
pp. 1394-1399 ◽  
Author(s):  
E. M. Sweeney ◽  
K. T. Thakur ◽  
J. L. Lyons ◽  
B. R. Smith ◽  
J. Z. Willey ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Intravenous Tissue Plasminogen Activator ◽  
Tissue Plasminogen

scholarly journals GRP per capita and hospital characteristics associated with intravenous tissue plasminogen activator adherence rate: evidence from the Chinese Stroke Center Alliance

2021 ◽  
pp. svn-2020-000633
Author(s):  
Suxi Zheng ◽  
Tian Jie Lyu ◽  
Zixiao Li ◽  
Hongqiu Gu ◽  
Xin Yang ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Emergency Services ◽  
Influential Factors ◽  
Adherence Rate ◽  
Intravenous Tissue Plasminogen Activator ◽  
Tissue Plasminogen ◽  
Per Capita ◽  
Stroke Center

BackgroundTimely delivery of intravenous tissue plasminogen activator (IV-rt PA) is pivotal to eligible patients who had a stroke while achieving higher rates of IV-rt PA has been problematic. This paper focuses on investigating influential factors associated with the administration of IV-rt PA, primarily per capita gross regional product (GRP) and healthcare system factors.MethodsThe study included 980 hospitals in the Chinese Stroke Center Alliance where 158 003 patients who had an acute ischaemic stroke received IV-rt PA between August 2015 and August 2019. The adherence rate to IV-rt PA within 4.5 hours time window in each hospital was the primary outcome. Influential factors were grouped into two categories: macroeconomic status and hospital characteristics. The outcome was analysed using multivariable linear regression.ResultsGRP per capita (β=2.37, p<0.001), hospital stroke centre certification (β=3.77, p<0.001), number of neurologists (β=0.12, p<0.001), existence of emergency services for neurological treatment (β=7.43, p=0.014), presence of emergency department (β=10.03, p=0.019) and cooperating with emergency centre (β=4.65, p=0.029) were significantly positively associated with the adherence rate to IV-rt PA.ConclusionsHigher GRP per capita, affluent neurological personnel, well-equipped emergency services for neurological treatment and routine cooperation with the emergency centre were important for enhancing the adherence rate to IV-rt PA among patients who had an acute ischaemic stroke in China.

Tissue-plasminogen activator for acute ischaemic stroke

The Lancet ◽  
1997 ◽  
Vol 349 (9050) ◽  
pp. 504
Author(s):  
Paul Dorman ◽  
Peter Sandercock
Keyword(s):  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Tissue Plasminogen

Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke

2001 ◽  
Vol 19 (9) ◽  
pp. 927-936 ◽  
Author(s):  
Shannon E. Sinclair ◽  
Luciana Frighetto ◽  
Peter S. Loewen ◽  
Rubina Sunderji ◽  
Philip Teal ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Acute Ischaemic Stroke ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Tissue Plasminogen
Sign in / Sign up

Export Citation Format

Share Document